Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09YUK
|
|||
| Former ID |
DIB011854
|
|||
| Drug Name |
SS1(dsFv)-PE38
|
|||
| Synonyms |
CAT-5001; SS (dsFv) PE38 immunotoxin); SS1-PE38; SS (dsFv) PE38 immunotoxin, NCI; SS1P, Enzon/NCI
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 1 | [1] | |
| Company |
National Cancer Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | . | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012262) | |||
| REF 2 | Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008 Jan;44(1):46-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.